Funds and ETFs Ever Supreme Bio Technology Co., Ltd

Equities

6712

TW0006712003

Pharmaceuticals

End-of-day quote Taipei Exchange 06:00:00 2024-04-28 pm EDT 5-day change 1st Jan Change
211 TWD +1.93% Intraday chart for Ever Supreme Bio Technology Co., Ltd +5.24% +7.93%

ETFs positioned on Ever Supreme Bio Technology Co., Ltd

Name Weight AuM 1st Jan change Investor Rating
0.04% 2 M€ -.--%
Ever Supreme Bio Technology Co., Ltd. is a Taiwan-based company mainly engaged in the research, design, development, manufacture and sales of stem cell products and immune cell products. The Company has three main products. ADCV01 is an autologous dendritic cell tumor vaccine product, which is currently in the phaseII of clinical trials in Taiwan. UMSC01 is a human allogeneic umbilical cord stem cell product and a new drug for the treatment of myocardial infarction, which is approved by the United States Food and Drug Administration (FDA) clinical phaseI and is currently applying for the phaseI of clinical trials in Taiwan. UMSC01 is a human allogeneic umbilical cord stem cell product, which is used to treat acute ischemic stroke and is currently in the United States FDA for clinical phase I. The Company plans to develop new products and services including mesenchymal stem cells for the treatment of multiple sclerosis.
More about the company

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. 6712 Stock
  4. Funds and ETFs Ever Supreme Bio Technology Co., Ltd